Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
CRO
Charles River and Valo pact nets preclinical lupus asset
The small molecule is an inhibitor designed for an autoimmune target that no other therapies go after.
Darren Incorvaia
Mar 26, 2025 6:30am
Merck KGaA fails lupus trial arm, plans further development
Mar 6, 2025 7:25am
Cabaletta's CAR-T shows 'robust benefit' in autoimmune patients
Feb 19, 2025 11:10am
Conduit taps Charles River to build AZ asset’s autoimmune cred
Feb 13, 2025 12:51pm
Biogen taps Royalty for $250M to fund phase 3 lupus program
Feb 12, 2025 8:10am
Cullinan CEO sets tone for bispecific's upcoming lupus readout
Feb 7, 2025 5:00am
